japanese
UCB scores Japanese approval for seizure therapy, Vimpat
July 5, 2016Manufacturing and Production, Research and Development Daiichi Sankyo, Japan, UCB, japanese
UCB Biopharma (EURONEXT: UCB) and Daiichi Sankyo have announced that Vimpat (lacosamide) has been approved as an adjunctive therapy in …
Latest content
Highlighting the value of lab research for healthcare innovation
November 2, 2026
Medtronic secures CE Mark for new cardiac pacing portfolio
October 30, 2026
Dermatology leader Doncker is new Onicor CEO
October 29, 2026
